Tan Huiping, Hu Shifu, Chen Yuan, Jin Lei, Wu Chunlin
Reproductive Medicine Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Geburtshilfe Frauenheilkd. 2019 Jul;79(7):713-722. doi: 10.1055/a-0837-3246. Epub 2019 Apr 1.
The fertility success rates of clinical and laboratory-assisted reproductive techniques (ART) remain low, despite major advances. The aim of this study was to conduct a systematic literature review and assess whether the intrauterine administration of human chorionic gonadotropin (hCG) before embryo transfer (ET) improved the clinical outcomes of sub-fertile women undergoing assisted reproduction. The electronic databases PUBMED, EMBASE and Web of Science were systematically searched for randomized controlled trials (RCTs) published from inception to June 2018. The trial data were independently extracted and analyzed using risk ratios (RRs) and 95% confidence intervals (CIs) according to a random- or fixed-effect model (as appropriate), and a meta-analysis was conducted using Review Manager 5.2 software. The meta-analysis included 3241 patients from 12 RCTs, and the combined results demonstrated that intrauterine hCG injection significantly improved the rates of clinical (RR = 1.33; 95% CI: 1.12 - 1.58) and ongoing pregnancy (RR = 1.87; 95% CI: 1.54 - 2.27), compared with controls. However, intrauterine hCG injection had no significant effect on the implantation rate (RR = 1.30; 95% CI: 0.89 - 1.90), abortion rate (RR = 1.06; 95% CI: 0.78 - 1.44), ectopic pregnancy rate (RR = 0.77; 95% CI: 0.17 - 3.42) or live birth rate (RR = 0.99; 95% CI: 0.60 - 1.63). In a subgroup analysis, the intrauterine injection of > 500 IU hCG led to a significant increase in the implantation rate (RR = 1.64; 95% CI: 1.04 - 2.61) relative to controls. Furthermore, the subgroup of women with cleavage-stage ETs who received an intracavity injection of hCG (IC-hCG) exhibited increases in the implantation, clinical pregnancy and ongoing pregnancy rates, compared to women with cleavage-stage ETs and no IC-hCG. The current evidence indicates that intrauterine hCG administration before ET provides an advantage in terms of the clinical pregnancy and ongoing pregnancy rates.
尽管取得了重大进展,但临床和实验室辅助生殖技术(ART)的生育成功率仍然很低。本研究的目的是进行一项系统的文献综述,并评估胚胎移植(ET)前宫腔内注射人绒毛膜促性腺激素(hCG)是否能改善接受辅助生殖的亚生育妇女的临床结局。系统检索了电子数据库PUBMED、EMBASE和科学网,以查找从创刊至2018年6月发表的随机对照试验(RCT)。根据随机或固定效应模型(视情况而定),独立提取试验数据并使用风险比(RR)和95%置信区间(CI)进行分析,并使用Review Manager 5.2软件进行荟萃分析。荟萃分析纳入了来自12项RCT的3241例患者,综合结果表明,与对照组相比,宫腔内注射hCG显著提高了临床妊娠率(RR = 1.33;95% CI:1.12 - 1.58)和持续妊娠率(RR = 1.87;95% CI:1.54 - 2.27)。然而,宫腔内注射hCG对着床率(RR = 1.30;95% CI:0.89 - 1.90)流产率(RR = 1.06;95% CI:0.78 - 1.44)、异位妊娠率(RR = 0.77;95% CI:0.17 - 3.42)或活产率(RR = 0.99;95% CI:0.60 - 1.63)没有显著影响。在亚组分析中,相对于对照组,宫腔内注射>500 IU hCG导致着床率显著增加(RR = 1.64;95% CI:1.04 - 2.61)。此外,与接受卵裂期胚胎移植且未进行宫腔内注射hCG(IC - hCG)的女性相比,接受卵裂期胚胎移植并进行宫腔内注射hCG的女性着床率、临床妊娠率和持续妊娠率均有所增加。目前的证据表明,胚胎移植前宫腔内注射hCG在临床妊娠率和持续妊娠率方面具有优势。